Nasdaq · CIK 0001517022
AKBA Akebia Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 1, 2025. Close $0.80 on Oct 9, 2026, 0% from the 52-week low and -75% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
AKBAOct 9, 2026 · close 0.80
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Akebia Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Erik Ostrowski SVP, CFO, CBO & Treasurer sell | $152k 41,314 shares | -8% | +184% from low-8% from high | |
| 0Weak | Richard C Malabre SVP, Chief Accounting Officer sell | $60k 15,000 shares | -5% | +199% from low-4% from high | |
| 1Weak | Richard C Malabre SVP, Chief Accounting Officer sell | $47k 13,334 shares | -5% | +184% from low0% from high | |
| 3Weak | Steven Keith Burke SVP, Chief Medical Officer sell | $13k 7,144 shares | -1% | - | |
| 22Weak | John P. Butler CEO and President sell | $85k 46,409 shares | -2% | - | |
| 25Weak | Nicholas Grund Chief Commercial Officer sell | $117k 55,621 shares | -11% | - | |
| 18Weak | Richard C Malabre SVP, Chief Accounting Officer sell | $63k 30,202 shares | -10% | - | |
| 20Weak | Steven Keith Burke SVP, Chief Medical Officer sell | $106k 50,506 shares | -6% | - | |
| 34Weak | John P. Butler CEO and President sell | $303k 144,250 shares | -5% | - |
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | Erik Ostrowski SVP, CFO, CBO & Treasurer | SOpen-market sale Common Stock10b5-1 | -41,314 | $3.67 | $152k | 503,586 | Jul 1, 2025 |
| Jun 10, 2025 | Adrian Adams director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 200,500 | Jun 11, 2025 |
| Jun 9, 2025 | Richard C Malabre SVP, Chief Accounting Officer | MOption exercise Common Stock10b5-1 | +15,000 | $1.68 | $25k | 281,914 | Jun 11, 2025 |
| Jun 10, 2025 | Leanne M Zumwalt director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 109,400 | Jun 11, 2025 |
| Jun 10, 2025 | Myles Wolf director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 133,381 | Jun 11, 2025 |
| Jun 10, 2025 | Cynthia Smith director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 160,933 | Jun 11, 2025 |
| Jun 10, 2025 | Michael W Rogers director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 161,729 | Jun 11, 2025 |
| Jun 10, 2025 | Steven C Gilman director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 152,830 | Jun 11, 2025 |
| Jun 10, 2025 | Ron Frieson director | AGrant or award Common Stock | +35,700 | $0.00 | $0 | 129,500 | Jun 11, 2025 |
| Jun 10, 2025 | Steven C Gilman director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Michael W Rogers director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Cynthia Smith director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Ron Frieson director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Myles Wolf director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Leanne M Zumwalt director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 10, 2025 | Adrian Adams director | AGrant or award Stock Option (Right to buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jun 11, 2025 |
| Jun 9, 2025 | Richard C Malabre SVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $4.01 | $60k | 266,914 | Jun 11, 2025 |
| Jun 9, 2025 | Richard C Malabre SVP, Chief Accounting Officer | MOption exercise Stock Option (Right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 321,000 | Jun 11, 2025 |
| Jun 4, 2025 | Richard C Malabre SVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -13,334 | $3.53 | $47k | 266,914 | Jun 5, 2025 |
| Mar 3, 2025 | John P. Butler CEO and President | SOpen-market sale Common Stock10b5-1 | -46,409 | $1.83 | $85k | 2,557,921 | Mar 4, 2025 |
| Mar 3, 2025 | Steven Keith Burke SVP, Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -7,144 | $1.83 | $13k | 809,090 | Mar 4, 2025 |
| Jan 31, 2025 | John P. Butler CEO and President | AGrant or award Common Stock10b5-1 | +701,000 | $0.00 | $0 | 2,748,580 | Feb 4, 2025 |
| Jan 31, 2025 | Steven Keith Burke SVP, Chief Medical Officer | AGrant or award Common Stock10b5-1 | +194,900 | $0.00 | $0 | 866,740 | Feb 4, 2025 |
| Jan 31, 2025 | Erik Ostrowski SVP, CFO, CBO & Treasurer | AGrant or award Common Stock | +194,900 | $0.00 | $0 | 544,900 | Feb 4, 2025 |
| Jan 31, 2025 | Nicholas Grund Chief Commercial Officer | AGrant or award Common Stock10b5-1 | +194,900 | $0.00 | $0 | 498,200 | Feb 4, 2025 |
| Jan 31, 2025 | Richard C Malabre SVP, Chief Accounting Officer | AGrant or award Common Stock10b5-1 | +85,000 | $0.00 | $0 | 310,450 | Feb 4, 2025 |
| Feb 3, 2025 | Nicholas Grund Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -55,621 | $2.10 | $117k | 442,579 | Feb 4, 2025 |
| Feb 3, 2025 | Richard C Malabre SVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -30,202 | $2.10 | $63k | 280,248 | Feb 4, 2025 |
| Feb 3, 2025 | Steven Keith Burke SVP, Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -23,270 | $2.10 | $49k | 843,470 | Feb 4, 2025 |
| Feb 3, 2025 | John P. Butler CEO and President | SOpen-market sale Common Stock10b5-1 | -46,268 | $2.10 | $97k | 2,702,312 | Feb 4, 2025 |
| Jan 31, 2025 | Erik Ostrowski SVP, CFO, CBO & Treasurer | AGrant or award Stock Option (Right to buy)derivative | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
| Jan 31, 2025 | Nicholas Grund Chief Commercial Officer | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
| Jan 31, 2025 | Richard C Malabre SVP, Chief Accounting Officer | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +128,000 | $0.00 | $0 | 128,000 | Feb 4, 2025 |
| Feb 3, 2025 | John P. Butler CEO and President | SOpen-market sale Common Stock10b5-1 | -97,982 | $2.10 | $206k | 2,604,330 | Feb 4, 2025 |
| Feb 3, 2025 | Steven Keith Burke SVP, Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -27,236 | $2.10 | $57k | 816,234 | Feb 4, 2025 |
| Jan 31, 2025 | Steven Keith Burke SVP, Chief Medical Officer | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
| Jan 31, 2025 | John P. Butler CEO and President | AGrant or award Performance Stock Unitsderivative10b5-1 | +350,500 | $0.00 | $0 | 350,500 | Feb 4, 2025 |
| Jan 31, 2025 | John P. Butler CEO and President | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +1,051,400 | $0.00 | $0 | 1,051,400 | Feb 4, 2025 |
| Jan 17, 2025 | Ron Frieson director | MOption exercise Common Stock | +20,100 | $0.45 | $9,045 | 93,800 | Jan 22, 2025 |
| Jan 17, 2025 | Ron Frieson director | MOption exercise Stock Option (Right to buy)derivative | -20,100 | $0.00 | $0 | 0 | Jan 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Adrian Adamsdirector
- Steven Keith BurkeSVP, Chief Medical Officer
- John P. ButlerCEO and President
- Ron Friesondirector
- Steven C Gilmandirector
- Nicholas GrundChief Commercial Officer
- Richard C MalabreSVP, Chief Accounting Officer
- Erik OstrowskiSVP, CFO, CBO & Treasurer
- Michael W Rogersdirector
- Cynthia Smithdirector
- Myles Wolfdirector
- Leanne M Zumwaltdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.